Inovalon Holdings, Inc. - (INOV): Price and Financial Metrics


Inovalon Holdings, Inc. - (INOV): $25.28

0.16 (+0.64%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

INOV Stock Summary

  • Inovalon Holdings Inc's stock had its IPO on February 12, 2015, making it an older stock than only 21.3% of US equities in our set.
  • With a price/earnings ratio of 178.12, Inovalon Holdings Inc P/E ratio is greater than that of about 94.72% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for INOV is currently 26.66, higher than 80.45% of US stocks with positive operating cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Inovalon Holdings Inc are NGVT, JELD, PGRE, EVOP, and SUM.
  • INOV's SEC filings can be seen here. And to visit Inovalon Holdings Inc's official web site, go to www.inovalon.com.

INOV Stock Price Chart Interactive Chart >

Price chart for INOV

INOV Price/Volume Stats

Current price $25.28 52-week high $28.75
Prev. close $25.12 52-week low $13.39
Day low $24.67 Volume 1,094,818
Day high $25.56 Avg. volume 721,805
50-day MA $23.82 Dividend yield N/A
200-day MA $22.39 Market Cap 3.93B

Inovalon Holdings, Inc. - (INOV) Company Bio


Inovalon Holdings provides advanced cloud-based data analytics and data-driven intervention platforms to the healthcare industry in the United States. The company was founded in 1998 and is based in Bowie, Maryland.

INOV Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$25.28$4.48 -82%

We started the process of determining a valid price forecast for Inovalon Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Inovalon Holdings Inc ranked in the 18th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for INOV, they are:

  • The stock's equity weight, or the proportion of capital from equity relative to debt, is 79. Its equity weight surpasses that of merely 21.06% of free cash flow generating stocks in the Technology sector.
  • Inovalon Holdings Inc's weighted average cost of capital (WACC) is 10%; for context, that number is higher than 67.6% of tickers in our DCF set.
  • Inovalon Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than merely 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-82%
1%-82%
2%-82%
3%-82%
4%-81%
5%-81%

Want more companies with a valuation profile/forecast similar to that of Inovalon Holdings Inc? See PTC, WK, CNXN, PAYC, and ANSS.


INOV Latest News Stream


Event/Time News Detail
Loading, please wait...

INOV Latest Social Stream


Loading social stream, please wait...

View Full INOV Social Stream

Latest INOV News From Around the Web

Below are the latest news stories about Inovalon Holdings Inc that investors may wish to consider to help them evaluate INOV as an investment opportunity.

Inovalon Lauded by Frost & Sullivan for Continuously Advancing Data-Driven Healthcare with Its Cloud-Based Inovalon ONE® Platform

Based on its recent analysis of the North American healthcare and life sciences analytics cloud solutions market, Frost & Sullivan recognizes Inovalon (Nasdaq: INOV) with the 2021 North American Company of the Year Award. Inovalon's cloud-based solution, the Inovalon ONE® Platform, enhances the operations of healthcare payers, providers, life sciences, and pharmacy organizations by helping them improve clinical quality outcomes and economics. The company empowers clients to harness comprehensive industry connectivity, massive primary-source real-world datasets, and healthcare data analytics to meet their end goals successfully.

Yahoo | February 23, 2021

AIDS Healthcare Foundation Selects the Inovalon ONE® Platform

World’s Largest Provider of HIV/AIDS Medical Care Will Implement ScriptMed® Cloud to Improve Clinical Outcomes for PatientsBOWIE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced an 8-year engagement with the AIDS Healthcare Foundation (AHF), the world’s largest provider of HIV/AIDS medical care. The engagement will provide cloud-based capabilities delivered through the Inovalon ONE® Platform and will support AHF’s data-driven strategy to improve clinical and quality outcomes and economics for its more than 1.5 million patients in 45 countries. The HIV epidemic is one of the major focuses in pharmacy today, with 1.1 million people in the U.S. living with the disease and an estim...

Yahoo | February 8, 2021

Inovalon Holdings, Inc. (INOV) CEO Keith Dunleavy on Q4 2020 Results - Earnings Call Transcript

Inovalon Holdings, Inc. (INOV) Q4 2020 Earnings Conference Call February 03, 2021, 17:00 ET Company Participants Kim Collins - SVP, Corporate Marketing & Communications Keith Dunleavy - Founder, Chairman & CEO Jonathan Boldt - CFO Conference Call Participants Glen Santangelo - Guggenheim Securities Raymond Xu - Morgan Stanley Jessica Tassan...

SA Transcripts on Seeking Alpha | February 4, 2021

Inovalon Supports Centers for Medicare and Medicaid Services with Software Application for COVID-19 Vaccine Administration

Application Provides Payment Processes Support for Providers Administering COVID-19 VaccinationsBOWIE, Md., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, today announced that its ABILITY PC-ACE software application is being distributed to help support COVID-19 vaccination administration and ensure uninterrupted remuneration processes for providers across the country. With the nationwide distribution of COVID-19 vaccines underway, it is essential that healthcare providers across the country be able to maintain their focus on delivering quality patient care and administer the vaccine without concerns regarding relevant data submission and protracted reimbursement timelines for services rendered. Me...

Yahoo | January 26, 2021

Inovalon Reports Preliminary Fourth Quarter 2020 Results

Prior Sales Implementations on Schedule, Driving Q4 Revenue up 17% Sequentially Sales Momentum Accelerating with All-Time Quarterly Record New Sales ACV of $93.5 MillionReiterating Strong 2021 Revenue and Profitability Growth GuidancePreliminary Expected Fourth Quarter 2020 Highlights * Total revenue of $189.0 to $190.0 million, up 9% YoY, and 17% sequentially * Subscription-based platform revenue of $163.0 million to $163.5 million, up 14% YoY, equating to 86% of Q4 2020 total revenue, and up 15% sequentially * Income before taxes of $17.0 million to $19.0 million, up 234% YoY and 800% sequentially * Adjusted EBITDA of $67.0 to $69.0 million, resulting in Adjusted EBITDA margin of 35.4% to 36.3% * Total new sales Annual Contract Value (ACV)1 totaled $93.5 million, up 27% YoY and ...

Yahoo | January 11, 2021

Read More 'INOV' Stories Here

INOV Price Returns

1-mo -1.21%
3-mo 37.39%
6-mo 4.42%
1-year 29.51%
3-year 108.07%
5-year 43.88%
YTD 39.13%
2020 -3.45%
2019 32.72%
2018 -5.47%
2017 45.63%
2016 -39.41%

Continue Researching INOV

Want to see what other sources are saying about Inovalon Holdings Inc's financials and stock price? Try the links below:

Inovalon Holdings Inc (INOV) Stock Price | Nasdaq
Inovalon Holdings Inc (INOV) Stock Quote, History and News - Yahoo Finance
Inovalon Holdings Inc (INOV) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8744 seconds.